Treatment with PI3Kα specific inhibitor alpelisib together fulvestrant increased progression-free survival of ER+ advanced breast cancer with PIK3CA mutations that had received endocrine therapy previously [10]. This evidence concerns the gene ESR1 and breast carcinoma.